DiagnaMed Accelerates Commercialization of CERVAI™ Brain Health AI Platform with Acceptance into the SOPHIE Program
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB:DGNMF), a generative artificial intelligence healthcare company, is pleased to announce it has been accepted into the Southern Ontario Pharmaceutical & Health Innovation Ecosystem (“SOPHIE”) Program to accelerate the clinical and commercialization efforts in Canada for the Company’s CERVAI™ Brain Health AI Platform. The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage funding to work directly with an academic or hospital partner in Hamilton’s ecosystem, such as McMaster University, Mohawk College, Hamilton Health Sciences, and St Joseph’s Health Centre Foundation.
Related news for (DGNMF)
- DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
- DiagnaMed Cancels Previously Announced Private Placement
- DiagnaMed Announces LIFE Offering of up to $650,000
- DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
- DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI